Navigation Links
PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
Date:12/2/2008

Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.

Fairfax, VA (PRWEB) December 2, 2008 -- Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.

"Cell Culture Manufacturing Capacity: Trends and Outlook through 2013" provides a timely and detailed examination of these issues. In this definitive report, foremost experts BioProcess Technology Consultants and PharmSource Information Services provide an extensive supply and demand analysis in addition to in-depth recommendations for the cell culture industry. Detailed data points include: product pipeline analysis, probable product success rates, time to market, API requirements, current and planned capacity, process yields and the potential impact of technology advances including biosimilars. "This report offers valuable strategic insight to support critical 'make or buy' decisions for mammalian cell culture manufacturers, key recommendations for capital investments and clear pricing strategy direction for the biologics contract manufacturing industry," comments BioProcess Technology Consultants president and founder Howard L. Levine, Ph.D. PharmSource president and founder, Jim Miller, concurs, "At a time of so much uncertainty in the biopharmaceutical industry, this analysis provides decision makers with the in-depth understanding they need to may critical API supply decisions."

The $4,950 report will be offered at the $700 pre-order discount price of $4,250 through December 15, 2008. For more detailed information and ordering instructions visit: http://www.pharmsource.com/forms.cfm?id=32.

About the Authors:
Founded in 1994, BioProcess Technology Consultants, Inc. is the leading providers of strategic, technical, operational, and regulatory consulting services to the biopharmaceutical industry and the industry's foremost expert on cell culture manufacturing. The company specializes in helping clients speed their products from clone to commercial®. Visit BioProcess Technology Consultants on the web at http://www.bioprocessconsultants.com or contact them at 978-266-9113.

PharmSource Information Services, Inc. is a respected provider of contract drug development and manufacturing intelligence. Since 1996 PharmSource has assisted Biotechnology and Pharmaceutical companies with the implementation and management of sourcing strategies and tactics through insightful publications, analyses and intelligence services. Visit PharmSource on the web at http://www.pharmsource.com or contact them at 703-383-4903.

###

Read the full story at http://www.prweb.com/releases/2008/12/prweb1691734.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS
2. PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma
3. Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement
4. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
5. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
6. Science Teachers Tour Ventrias Bioprocessing Facility
7. Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers
8. 2010 Japan Prize to Honor Scientists and Researchers in Industrial Production/Production Technology and Biological Production/Environment Fields
9. New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric
10. Micromet Added to NASDAQ Biotechnology Index
11. Aldrich(R) Releases Materials Science Catalog That Includes Products to Advance Sustainable Energy and Nanotechnology Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):